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Granulocyte–Macrophage Colony-Stimulating Factor
Is Essential for Normal Wound Healing
Amrit Mann1, Kerstin Niekisch2, Peter Schirmacher3 and Manfred Blessing1
Granulocyte–macrophage colony-stimulating factor (GM-CSF) is a multipotent growth factor, which plays an
important role during the process of wound healing. In clinical settings it has occasionally been employed in
the treatment of cutaneous wounds of diverse etiologies. In a previous study, we have shown the positive
influence of GM-CSF on full thickness excisional wounds in transgenic mice overexpressing GM-CSF in the
basal layer of the epidermis. Direct GM-CSF action as well as indirect processes through the induction of
secondary cytokines were proposed to contribute towards the beneficial effects. In this study, we analyzed the
process of wound healing in transgenic mice overexpressing a GM-CSF antagonist in the epidermis. These mice
not only exhibited a delayed scab rejection and reepithelialization but also neovascularization was reduced. The
newly formed tissue was of poor quality as exhibited by the presence of extensive fibrosis. We suggest that the
presence of GM-CSF in the repair process is of basic importance and its absence leads not only to delayed
wound healing but it is also detrimental for the quality of the newly formed tissue.
Journal of Investigative Dermatology Symposium Proceedings (2006) 11, 87–92. doi:10.1038/sj.jidsymp.5650013
INTRODUCTION
Long-lasting, nonhealing wounds of different etiologies present
a major problem in different disciplines of medicine, and are a
major source of disabilities, morbidity, and mortality. Causes
of poor wound healing and factors leading to enhanced
wound healing are of major interest but are poorly understood.
Wound healing is a complex but well-orchestrated process
involving cellular and extracellular components leading to at
least partial reconstitution of the wounded tissue (Singer and
Clark, 1999). The initiation of wound healing involves
sequential completion of coagulation, inflammation, cellular
proliferation and migration, angiogenesis, matrix synthesis,
remodeling, and wound contraction (Martin, 1997; Stadel-
mann et al., 1998; Baker and Leaper, 2000). Cytokines such
as platelet-derived growth factor, epidermal growth factor,
keratinocyte growth factor, transforming growth factor beta,
fibroblast growth factor, ILs, chemokines, and their respective
receptors coordinate different steps of the wound healing. In
the past 10 years only few of these growth factors, for
example, platelet-derived growth factor have been approved
by the Food and Drug Administration for treatment of patients
(Rees et al., 1999; Fu et al., 2005).
Although the mechanisms by which granulocyte–macro-
phage colony-stimulating factor (GM-CSF) influences wound
healing have only been partly elucidated, GM-CSF has been
analyzed in diverse animal and preclinical studies in this
respect. GM-CSF has been employed in the treatment of
poorly healing wounds of diverse etiologies with some
success (El Saghir et al., 1997; Canturk et al., 1999; Jaschke
et al., 1999; Stagno et al., 1999; Voskaridou et al., 1999;
Siddiqui et al., 2000; Jorgensen et al., 2002; Mery et al.,
2004). GM-CSF mRNA is detectable shortly after epidermal
activation, for example, through wounding or application of a
tumor promoter like TPA (Robertson et al., 1994; Pastore
et al., 1997). It is hypothesized that GM-CSF influences the
biologic activities of several hematopoietic and nonhemato-
poietic cells that take part in the tissue repair (Hancock et al.,
1988; Bussolino et al., 1991; Shephard et al., 2004). In this
respect, GM-CSF influences major aspects of the repair
process, that is, inflammation, reepithelialization, and
neovascularization. Impairment of any of these processes
would result in chronic nonhealing wounds.
To identify the mechanisms underlying the in vivo effects
of GM-CSF on wound healing, we modified the activity of
GM-CSF in transgenic animals. A double mutant ligand
(K14E/E21K) used to generate the K10-GM-CSF antagonist
transgenics, had been shown to bind to the a-chain of
GM-CSF receptor but failed to stimulate the signal-transducing
b-chain of the receptor complex (Altmann and Kastelein,
1995). These animals exhibited high GM-CSF antagonist levels
in skin extracts. It could be shown that the GM-CSF signaling is
blocked in the skin of these animals as the antagonist was able
to suppress GM-CSF-dependent keratinocyte proliferation and
LC accumulation in vivo (Mann et al., 2001b).
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In a previous study, we could show the beneficial effects
of GM-CSF in wound healing in a transgenic mouse model
overexpressing GM-CSF in the basal layer of the epidermis. It
was proposed that the beneficial effects of GM-CSF are not
only the direct effects but also indirect effects via the
induction of secondary cytokines (Mann et al., 2001a). In
the present study conducted in transgenic mice overexpres-
sing an antogonist of GM-CSF in the epidermis, these mice
exhibited delayed scab rejection and reepithelialization and
extensive fibrosis in the newly formed matrix. These effects
result from reduced keratinocyte proliferation, reduced
neovascularization, and extensive deposition of collagen.
Therefore, GM-CSF is not only beneficial for wound repair
but it is also required for timely and high-quality wound
healing.
RESULTS
Scab rejection is delayed in GM-CSF antagonist transgenics.
In total, 10 transgenic and wild-type control animals were
wounded as described in Materials and Methods. Gross
appearance of wounds, incidence of infection, and scab
rejection were documented daily. At 3–4 days after wound-
ing, wounds in the GM-CSF antagonist transgenics had a
glistening moist appearance and exhibited only thin scabs,
whereas the wounds in the wild-type animals were dry and
covered with a proper scab at this point.
Also the differences in scab rejection were significant.
GM-CSF antagonists exhibited a delayed onset of scab
rejection as compared to the wild-type controls (Figure 1).
At day 7 postwounding, 20% of the wild-type control animals
had lost their scabs, whereas the first scabs were lost on day 8
(10%) in the antagonist transgenics. By day 9 after wounding
only 40% of the scabs were shed in antagonist transgenics as
compared to 60% wild-type controls. In GM-CSF antagonists,
which had lost the scab at 8–9 days after wounding, the
wound was oozing and got a dry, scaly appearance in the
following couple of days. Antagonist transgenics needed as
many as 14 days till all the scabs were shed, whereas all the
wild-type animals had lost the scabs by day 11 after
wounding. Also, major differences were observed in the
gross appearance of the wounds after scab rejection. At
2 weeks after wounding, the middle of the wound had a scaly
crust in the GM-CSF antagonist transgenics, whereas in the
control group the wound area could only be recognized due
to the lower hair density.
GM-CSF antagonist transgenics exhibit delayed reepithe-
lialization of wounds. Reepithelialization is an important
aspect of the repair process. GM-CSF overexpression has
been associated with enhanced reepithelialization and tissue
remodeling (Mann et al., 2001b). Sections through the middle
of the wounds were cut at different time points after
wounding and stained routinely with hematoxylin and eosin,
and the extent of reepithelialization was documented.
Significant differences were observed in the extent of
reepithelialization between GM-CSF antagonist transgenics
and wild-type controls. Complete reepithelialization was
delayed in the antagonist transgenics in comparison to the
control animals as exemplified in Figure 2a–d. Also on a
quantitative basis, these animals exhibited significantly
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Figure 1. Scab rejection postwounding. Ten transgenic animals overexpres-
sing GM-CSF antagonist in skin and their littermate controls were wounded
and observed on a daily basis for scab rejection. Note the delayed scab
rejection in the transgenic animals as compared to the wild-type controls.
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Figure 2. Progress in wound healing. (a–d) Wild-type control animals as well
as animals overexpressing a GM-CSF antagonist were wounded. Wounds
were removed and prepared for hematoxylin/eosin staining. Five animals per
genotype and time point were taken for the analysis. (a and c) Stained sections
from control animals and ( b and d) represent sections from the transgenic
animals at 3 days (a and b) and 10 days (c and d) postwounding. Note the
differences in scab formation and scab rejection, granulation tissue formation,
and reepithelialization between the transgenic and the control animals. Bars:
200mm. (e) Histograph showing % reepithelialization. HE stained sections
were evaluated in a double-blinded manner for the extent of reepithelializa-
tion by morphometry and % reepithelialization was quantified. Note the
longer time needed by the antagonists for the complete closure of wound.
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delayed reepithelialization as compared to the wild-type
animals (Figure 2e).
Furthermore, differences in the granulation tissue forma-
tion were observed in these groups. Even though abundant
granulation tissue formation in the antagonist transgenics was
observed at earlier time points after wounding, a delay in
tissue remodeling was observed at later time points. This was
exhibited by the presence of scab, high dermal cellularity,
and absence of hair follicles indicative of reduced wound
contraction, in the newly formed tissue (Figure 2d). Also,
pronounced inflammation and monocytic lymphocytes in-
filtrate in the wound area in the antagonist transgenics at
3 days postwounding were observed (Figure 2b). A closer
analysis of the infiltrating cells exhibited twice as many
neutrophils in the granulation tissue in the antagonist
transgenic animals as compared to the wild-type controls at
day 7, postwounding, whereas the numbers of mast cells
were reduced in the antagonist transgenics at this time point.
No significant differences in the numbers of T cells and
macrophages could be detected (data not shown).
GM-CSF antagonists exhibit diminished mitotic indices.
Under normal conditions, mitotic indices in the basal layer of
the interfollicular epidermis in the GM-CSF antagonists are
comparable to those in the wild-type controls (Mann et al.,
2001b). The GM-CSF antagonists behaved comparable to the
wild-type controls at earlier time points after wounding so
that a maximum on proliferation rate was achieved on day 3
after wounding (Figure 3a, b, and e). At 10 days after
wounding, proliferation is still higher in these animals, albeit
significantly lower as compared to the wild-type controls
(Figure 3c–e).
GM-CSF antagonists exhibit reduced neovascularization.
In order to determine the extent of microvessel formation,
sections through the middle of the wounds were stained with
an antibody directed towards CD31 (Figure 4). CD31 stained
vessels were counted and expressed as numbers per field.
Whereas the numbers of microvessels in the antagonist
transgenics before wounding are comparable to those in the
wild-type animals, the numbers at 7 and 10 days after
wounding are significantly reduced (Figure 4) pointing
towards a defect in neovascularization.
Wound healing in GM-CSF antagonists is accompanied by
extensive fibrosis. Since the wounds in antagonist transgenics
exhibited an obvious scar and extensive fibrosis in H&E
stained sections 14 days after wounding, the sections were
stained with Masson’s trichrom stain for collagen deposition.
As shown in the Figure 5, GM-CSF antagonist transgenics
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Figure 3. Keratinocyte proliferation rates during wound healing. (a–d) Mice
were injected intraperitonially with BrdUrd and killed after a labeling period
of 2 hours. Sections were stained using an anti-BrdUrd antibody as described
in the Materials and Methods. Five animals per genotype and time point were
analyzed. Shown are (a and c) control animals and, (b and d) transgenic
animals at (a and b) 3 and (c and d) 10 days postwounding, respectively. Both
controls and transgenic animals exhibit a proliferative burst at 3 days
postwounding; however, 10 days postwounding the transgenics exhibited
significantly less numbers of proliferating kerationcytes. Bars: 200 mm.
(e) Histograph showing the numbers of keratinocyte S-phase nuclei at the
wound margin. For this purpose BrdUrd-labeled nuclei were counted at the
wound margin and related to 100 total basal cells. Enhanced but comparable
rate of proliferation can be observed at 3 days postwounding in both
transgenics and the control animals. At 10 days postwounding, the antagonist
transgenics exhibit significantly lower proliferation rates (*Po0.05).
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Figure 4. Extent of neovascularization during the wound healing. Sections
through the middle of the wounds were stained with a CD31-specific
antibody for the detection of newly formed blood vesicles. The samples were
photographed and the numbers of microvessels per field were counted. Five
animals per genotype and time point were analyzed. Note the significantly
lower numbers of microvessels in the antagonist transgenic at all the observed
time points after wounding.
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exhibit late granulation tissue with extensive extracellular
matrix deposition (b) whereas the wild-type controls ex-
hibited only marginal extracellular matrix deposition at the
same time point (a). This exhibits that absence of GM-CSF is
detrimental during wound healing.
DISCUSSION
The process of wound healing is a precisely regulated
sequence of cellular and biochemical events leading to at
least partial restoration of tissue integrity after injury. In many
cases, however, the proliferative response produces a fibrotic
scar so that the injured organ is patched rather than restored
to its original state (Singer and Clark, 1999). GM-CSF exerts
its effects on wound healing through multiple mechanisms,
affecting nearly every aspect of the repair process. It is
synthesized by many cellular components of the repair
process like keratinocytes, fibroblasts, endothelial cells,
macrophages, and dendritic cells (Bussolino et al., 1991;
Caux et al., 1992; Braunstein et al., 1994; Breuhahn et al.,
2000). In this respect, it is a possible candidate and has
already been used in various preclinical studies aimed to heal
chronic ulcers of different origins (El Saghir et al., 1997;
Canturk et al., 1999; Stagno et al., 1999; Voskaridou et al.,
1999; Mery et al., 2004).
To identify the mechanisms underlying the in vivo effects
of GM-CSF on wound healing, we modified the expression of
GM-CSF in transgenic animals. In a previous study we could
show that overexpression of GM-CSF in the epidermis of
transgenic mice lead to an early healing of full thickness
cutaneous wounds (Mann et al., 2001a). In the present study,
transgenic mice overexpressing a GM-CSF antagonist were
used and the process of wound healing was investigated.
Here, we confirm not only the important role of GM-CSF in
the wound healing but also that the absence of this growth
factor is disadvantageous for the repair process.
GM-CSF has been shown to enhance keratinocyte
proliferation, migration, and survival in vivo and in vitro
(Hancock et al., 1988; Braunstein et al., 1994; Breuhahn
et al., 2000). Under normal circumstances, GM-CSF antago-
nist transgenics did not show any alterations in the mitotic
indices in the epidermis as compared to the wild-type mice,
but in double transgenic mice overexpressing both GM-CSF
and GM-CSF antagonist, GM-CSF antagonist was able to
suppress the GM-CSF-dependent keratinocyte hyperprolifera-
tion and LC accumulation of the keratinocytes (Mann et al.,
2001b). Therefore, lower keratinocyte proliferation rate in the
antagonist transgenics at day 10, postwounding in compari-
sion to the wild-type controls may be attributed to the
suppression of GM-CSF-dependent keratinocyte proliferation
by the antagonist. This is even true despite the fact that more
wounds were reepithelialized in the wild-type animals at this
time point as compared to the transgenic animals.
Neovascularization of the wound is of utmost importance
for the supply of vital components necessary for the repair
process. In our previous study, increased neovascularization
in mice overexpressing GM-CSF could be correlated to
enhanced wound healing (Mann et al., 2001a). On the
opposite mice overexpressing an antagonist of GM-CSF
exhibit reduced microvessel formation and delayed healing,
suggesting a direct relationship between GM-CSF and
neovascularization. GM-CSF has been shown to be an
important factor for endothelial cell proliferation and survival
(Bussolino et al., 1991). GM-CSF-dependent activation of IkB
kinase activity leading to subsequent activation of NFkB has
been shown to be an important factor for endothelial cell
proliferation and survival in vitro (Ebner et al., 2003). Plenz
et al. (2003) could show that GM-CSF deficiency leads to an
altered composition of the vascular collagenous matrix
suggesting an importance of GM-CSF for the maintenance
of vessel wall integrity and resilience.
Fibroblasts that invade the granulation tissue as the repair
progresses differentiate into myofibroblsts by acquiring
smooth muscle cell characteristics (Tomasek et al., 2002).
These express a-smooth muscle actin, which confers con-
tractile capacity to the wound tissue. Also, myofibroblasts are
the principle source of extracellular matrix components in the
granulation tissue (Oda et al., 1990). An important observa-
tion in the present study was the presence of extensive
fibrosis in the newly formed tissue. Relation of GM-CSF and
fibrosis has been discussed controversially in literature. On
the one hand, intradermal transgenic expression of GM-CSF
in rats by using a replication-deficient adenoviral vector lead
to upper dermal fibrosis besides inducing other dermal and
epidermal pathologies (Xing et al., 1997a). Also, overexpres-
sion of GM-CSF in lungs lead to an irreversible fibrotic
response in rats (Xing et al., 1997b). On the other hand, mice
a
b
Figure 5. Detection of fibrosis in the repair process. Section through the
middle of wounds were cut and stained with Masson’s Trichrome stain. Note
the extensive collagen deposition (Blue staining) in the (b) antagonist
transgenics at 14 days postwounding as compared to the (a) control animals.
Bars: 200mm.
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deficient in GM-CSF developed pulmonary fibrosis besides
developing pulmonary alveolar proteinosis (Dranoff et al.,
1994; Stanley et al., 1994). In another study, a direct relation
was observed in diminished levels of GM-CSF and bleomy-
cin-induced pulmonary fibrosis suggesting a protective role
for GM-CSF in bleomycin-induced pulmonary fibrosis
(Christensen et al., 2000). We suggest that GM-CSF plays a
complex role in fibrosis depending upon the circumstances
and exact mechanism needs to be investigated further. Many
cytokines, for example, platelet-derived growth factor,
epidermal growth factor, keratinocyte growth factor, trans-
forming growth factor beta, fibroblast growth factor and their
respective receptors have also been shown to influence
wound healing positively by coordinating different steps of
the repair process (Rees et al., 1999; Fu et al., 2005).
However, retarded wound healing in the GM-CSF antagonist
transgenics demonstrates that there is no redundancy for GM-
CSF mediated neovascularization, keratinocyte proliferation,
and tissue remodeling.
MATERIALS AND METHODS
Transgenic mouse line Tg2-Ant, overexpressing an antagonist of
GM-CSF (K14E/E21K) under the control of bovine keratin 10
promoter, has been described previously (Mann et al., 2001b).
These animals were maintained as hemizygotes on an FVB/N
background. Animals were housed and bred in the animal facility of
the Johannes Gutenberg University, Mainz, Germany. All experi-
mental procedures were in accordance with the governmental and
institutional guidelines.
Wounding protocol and analysis
Age and sex matched transgenic animals and their littermate
controls, aged 8–10 weeks were anesthetized by avertin. The backs
were shaved using electrical clippers and swabbed with 70%
ethanol. A single 5 mm diameter full-thickness wound was inflicted
on the mid-dorsum using a biopsy punch. The wound was left
without sutures or dressing. Subsequently, the animals were housed
individually. Four to five animals were analyzed per time point and
experiments were repeated.
The wounds were observed once per day for infection, formation,
and rejection of scab. At days 1, 3, 7, 10, and 14 postwounding, the
animals were euthanized and wound areas cleaned carefully. The
wound including 3–4 mm marginal nonwounded skin was carefully
excised. The wound was divided into two halves and processed for
cryosections and paraffin embedding.
Histology and immunohistology
Sections were cut at 5mm thickness, mounted on slides, and stained
routinely with hematoxylin and eosin. Evaluation of the wounds was
carried out by two investigators including a senior pathologist (P.S.).
Extent of reepithelialization was quantified by morphometry and
expressed as ‘‘% reepithelialization’’. Granulation tissue formation,
cellularity, architecture, and inflammation were also evaluated. An
antibody directed to CD31 (PECAM-1, Pharmingen, Germany) was
used to detect microvessels in the wound bed. Sections were also
stained routinely for fibrosis with Masson’s Trichrome stain (Sigma).
May–Gru¨nwald–Giemsa staining was performed to evaluate the
granulation tissue and naphthol AS-D chloroacetate estrase staining
was performed to detect neutrophilic granulocytes and their
precursors. The sections were also stained for T-cell subsets (CD4
and CD8) and for macrophages (CD11b) using specific antibodies
(Pharmingen, Germany).
Determination of mitotic indices
Proliferation indices were conveyed by BrdUrd labeling using In Situ
Cell Proliferation Kit, FLUOS (Roche, Mannheim, Germany). Mice
were injected intraperitonially with 30 mg BrdUrd per gram body
weight and killed after a labeling period of 2 hours. Fixation and
processing of the samples was carried out according to the
manufacturer’s instructions. The sections were further treated with
anti-FITC-AP antibody (DakoCytomation, Denmark) and signal
detection was carried out using Fast Red (Roche, Mannheim,
Germany) as substrate. The sections were counterstained with
Mayer’s hemalum (Merck, Darmstadt, Germany). The sections were
subsequently photographed and number of labeled nuclei in the
basal layer of the epidermis at the wound margin was related to total
100 basal cells. Values were obtained from at least four animals per
group and time point.
Statistics
Data are shown as mean7SD. Student’s t-test was used to analyze
the statistical significance in the differences between two groups.
Values of Po0.05 were considered significant.
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